Myriad Genetics Reports Board Changes and Compensation Updates
Ticker: MYGN · Form: 8-K · Filed: Oct 7, 2025 · CIK: 899923
| Field | Detail |
|---|---|
| Company | Myriad Genetics Inc (MYGN) |
| Form Type | 8-K |
| Filed Date | Oct 7, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01, $1,239,384 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation
Related Tickers: MYGN
TL;DR
MYGN board shakeup and comp changes filed 10/1.
AI Summary
Myriad Genetics, Inc. announced on October 1, 2025, a change in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and the election of new directors, alongside updates to compensatory arrangements for key personnel.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can introduce uncertainty regarding future strategy and operational stability.
Key Players & Entities
- MYRIAD GENETICS, INC. (company) — Registrant
- October 1, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 801-584-3600 (phone_number) — Registrant's telephone number
FAQ
What specific roles have seen departures or appointments?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' and 'Compensatory Arrangements of Certain Officers', suggesting shifts in leadership positions.
When did these changes take effect?
The earliest event reported in this filing occurred on October 1, 2025.
What is Myriad Genetics' primary business?
Myriad Genetics, Inc. is involved in 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES' as indicated by its SIC code.
Where is Myriad Genetics headquartered?
The company's principal executive offices are located at 322 North 2200 West, Salt Lake City, Utah 84116.
What type of SEC filing is this?
This is a Form 8-K, which is a Current Report filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 731 words · 3 min read · ~2 pages · Grade level 11.8 · Accepted 2025-10-07 16:02:13
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 par value MYGN Nasdaq Global Select Mar
- $1,239,384 — receive a lump sum severance payment of $1,239,384. In addition, (i) the vesting of all ou
Filing Documents
- mygn-20251001.htm (8-K) — 30KB
- ex101myriad-lefflerseparat.htm (EX-10.1) — 57KB
- 0000899923-25-000096.txt ( ) — 241KB
- mygn-20251001.xsd (EX-101.SCH) — 2KB
- mygn-20251001_def.xml (EX-101.DEF) — 14KB
- mygn-20251001_lab.xml (EX-101.LAB) — 25KB
- mygn-20251001_pre.xml (EX-101.PRE) — 15KB
- mygn-20251001_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
ITEM 9.01 Financial Statements and Exhibits. Exhibit Number Description 10.1+ Separation Agreement and Release of Claims, dated October 1 , 2025, by and between Myriad Genetics, Inc. and Scott J. Leffler. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). + Management contract or compensatory plan arrangement.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MYRIAD GENETICS, INC. Date: October 7, 2025 By: /s/ Benjamin R. Wheeler Benjamin R.Wheeler Chief Financial Officer